Media coverage about Coherus BioSciences (NASDAQ:CHRS) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Coherus BioSciences earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.643873944959 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

CHRS has been the subject of a number of recent research reports. BidaskClub cut shares of Coherus BioSciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $25.00 target price (down previously from $32.00) on shares of Coherus BioSciences in a research report on Tuesday, August 8th. Zacks Investment Research raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Tuesday, August 15th. ValuEngine raised shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Maxim Group reissued a “buy” rating and issued a $20.00 target price (down previously from $40.00) on shares of Coherus BioSciences in a research report on Friday, September 8th. Three equities research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $32.00.

Coherus BioSciences (CHRS) traded down 0.547% on Wednesday, reaching $13.625. The company had a trading volume of 212,214 shares. The stock’s market capitalization is $699.59 million. The stock’s 50-day moving average price is $13.51 and its 200-day moving average price is $16.13. Coherus BioSciences has a 12-month low of $10.80 and a 12-month high of $31.48.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.21. The company had revenue of $1.40 million during the quarter. Coherus BioSciences had a negative return on equity of 307.41% and a negative net margin of 73.89%. On average, equities research analysts anticipate that Coherus BioSciences will post ($5.13) EPS for the current fiscal year.

In other Coherus BioSciences news, insider Alan C. Herman sold 17,535 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $15.02, for a total value of $263,375.70. Following the completion of the transaction, the insider now owns 49,651 shares in the company, valued at approximately $745,758.02. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 26.28% of the stock is owned by company insiders.

WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2017/10/18/coherus-biosciences-chrs-given-daily-media-sentiment-score-of-0-20.html.

About Coherus BioSciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.